OST - OST

Ostin Technology Groupの空売り状況は、投資家がOstin Technology Groupの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Ostin Technology Group (NASDAQ:OST) 株価情報, 空売り情報

Ostin Technology Group

Ostin Technology Group Co Ltd is a supplier of display modules and polarizers in China. It designs, develops, and manufactures TFT-LCD modules in a wide range of sizes and customized sizes according to the specifications of its customers. Its display modules are mainly used in consumer electronics, commercial LCD displays, and automotive displays. The company also manufactures polarizers used in the TFT-LCD display modules and is in the process of developing polarizers for the OLED display panel. Geographically, the company generates revenue from Hong Kong, Taiwan, and Mainland China which is its key revenue generating market.

Ostin Technology Group Co., Ltd. - Class A Ordinary Shares

Ostin Technology Group Co Ltd

OSTERREICHISCHE PST S/ADR by Osterreichische Post AG

Oesterreichische Post AG

Original Sixteen to One Mine Inc

OSAKA TITANIUM TECH CO by OSAKA TITANIUM TECHNOLOGIES CO LTD.

OSAKA Titanium technologies Co Ltd

OS Therapies Inc

Sky Quarry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYQ#NASDAQ">SKYQ</a>) reported quarterly losses of $(0.16) per share. This is a 6.67 percent decrease over losses of $(0.15) per share from the same period last year. The company reported $6.33 million in sales this quarter. This is a 42.18 percent decrease over sales of $10.95 million the same period last year.

Earnings

News

SKYQ

Sky Quarry Q1 EPS $(0.16) Down From $(0.15) YoY, Sales $6.33M Down From $10.95M YoY

It&#8217;s been a roller coaster year for Wall Street as investors revise expectations during a period of <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45435725/tariffs-slow-retail-spending-as-producer-prices-post-sharpest-drop-since-2020">rapidly changing policy announcements</a> in the White House. While markets turned bearish in March and April as the Trump Administration threatened tariffs on several U.S. trade partners, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) retraced some of its losses as the administration backed off some of its policy commitments and <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45376487/wall-street-edges-higher-as-inflation-cools-nasdaq-100-hits-10-week-highs">economic indicators look promising</a>.
Stephanie Link, chief investment officer and portfolio manager at Hightower Advisors, is optimistic about the market&#8217;s prospects if tariff concerns can be averted.
&#8220;I think the biggest surprise is that the Atlanta Fed [GDPNow] is at 2.3% in the face of everything,&#8221; Link wrote on Thursday. &#8220;Consumer continues to spend — Walmart is proof of that. Labor market remains solid and inflation is coming down albeit slowly. EPS up 12% is impressive as well. Get through tariffs and we'll start to focus on more positive things — lower taxes and deregulation.&#8221;
Link noted two contrarian plays she is bullish on as 2025 enters its second half. She called Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) her &#8220;favorite stock for 2025&#8221; amid the company&#8217;s turnaround under new leadership. While the Arlington, Virginia-based company&#8217;s shares have fallen from all-time highs due to regulatory woes and safety concerns, its stock is up over 20% in 2025.
Link also highlighted private equity giant KKR &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) as a firm benefiting from several positive trends.
&#8220;Added KKR this past week [with] the stock down 15% ytd and a play on growth, real assets, infrastructure and fee growth,&#8221; Link said.
She noted Quanta Services Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>), Eaton Corporation PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) and Rockwell Automation Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) as other infrastructure plays.
Also Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45439079/powell-signals-fed-may-shift-its-inflation-strategy-after-5-year-economic-shake-up">Powell Signals Fed May Shift Inflation Strategy After 5 Years Of Economic Upheaval</a></li>
</ul>
Photo: Shutterstock

Equities

Hedge Funds

Exclusives

'My Favorite Stock For 2025,' Says Portfolio Manager, Who Also Notes Two Contrarian Plays During Growth Optimism

Femto Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FMTO#NASDAQ">FMTO</a>) reported quarterly losses of $(2.50 thousand) per share. The company reported $141.20 thousand in sales this quarter.

FMTO

Femto Technologies Q1 EPS $(2.50K), Sales $141.20K

Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) reported quarterly losses of $(1.61) per share. This is a 56.49 percent increase over losses of $(3.70) per share from the same period last year.

KTTA

Pasithea Therapeutics Q1 EPS $(1.61) Up From $(3.70) YoY

Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) reported quarterly losses of $(1.40) per share. This is a 87.93 percent increase over losses of $(11.60) per share from the same period last year.

VINC

Vincerx Pharma Q1 EPS $(1.40) Up From $(11.60) YoY

HOOKIPA Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOK#NASDAQ">HOOK</a>) reported quarterly losses of $(1.23) per share which missed the analyst consensus estimate of $(0.62) by 98.39 percent. This is a 211.82 percent decrease over earnings of $1.10 per share from the same period last year. The company reported quarterly sales of $2.00 million which missed the analyst consensus estimate of $3.38 million by 40.62 percent. This is a 94.52 percent decrease over sales of $36.60 million the same period last year.

Earnings Misses

HOOK

HOOKIPA Pharma Q1 EPS $(1.23) Misses $(0.62) Estimate, Sales $2.00M Miss $3.38M Estimate

Safety Shot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOT#NASDAQ">SHOT</a>) reported quarterly losses of $(0.08) per share. This is a 75.76 percent increase over losses of $(0.33) per share from the same period last year. The company reported $42.10 thousand in sales this quarter. This is a 75.34 percent decrease over sales of $170.73 thousand the same period last year.

SHOT

Safety Shot Q1 EPS $(0.08) Up From $(0.33) YoY, Sales $42.10K Down From $170.73K YoY

Momentus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTS#NASDAQ">MNTS</a>) reported quarterly losses of $(1.64) per share. This is a 82.25 percent increase over losses of $(9.24) per share from the same period last year. The company reported $322.00 thousand in sales this quarter. This is a 37.23 percent decrease over sales of $513.00 thousand the same period last year.

MNTS

Momentus Q1 EPS $(1.64) Up From $(9.24) YoY, Sales $322.00K Down From $513.00K YoY

Franklin Wireless (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FKWL#NASDAQ">FKWL</a>) reported quarterly losses of $(0.05) per share. This is a 50 percent increase over losses of $(0.10) per share from the same period last year. The company reported $8.01 million in sales this quarter. This is a 29.70 percent increase over sales of $6.18 million the same period last year.

FKWL

Franklin Wireless Q3 EPS $(0.05) Up From $(0.10) YoY, Sales $8.01M Up From $6.18M YoY

GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.64) by 48.44 percent. This is a 79.88 percent increase over losses of $(1.64) per share from the same period last year.

Earnings Beats

GTBP

GT Biopharma Q1 EPS $(0.33) Beats $(0.64) Estimate

HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) reported quarterly losses of $(0.05) per share. This is a 75 percent increase over losses of $(0.20) per share from the same period last year. The company reported $5.07 thousand in sales this quarter. This is a 99.55 percent decrease over sales of $1.13 million the same period last year.

HCWB

HCW Biologics Q1 EPS $(0.05) Up From $(0.20) YoY, Sales $5.07K Down From $1.13M YoY

Teva Pharmaceuticals (NYSE and TASE: TEVA)&nbsp;today announced that Moody's Investor Services ("Moody's") has raised the company's corporate credit rating to Ba1, outlook stable; from Ba2, outlook positive.

Analyst Ratings

Trading Ideas

TEVA

Teva Pharmaceuticals Announced That Moody's Investor Services Has Raised The Company's Corporate Credit Rating To Ba1, Outlook Stable From Ba2, Outlook Positive

Jones Soda (OTC:<a class="ticker" href="https://www.benzinga.com/stock/JSDA#OTC">JSDA</a>) reported quarterly losses of $(0.01) per share. This is unchanged from the same period last year. The company reported $4.61 million in sales this quarter. This is a 7.82 percent decrease over sales of $5.00 million the same period last year.

JSDA

Jones Soda Q1 EPS $(0.01), Same YoY, Sales $4.61M Down From $5.00M YoY

Pioneer Power Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPSI#NASDAQ">PPSI</a>) affirms FY2025 sales outlook from $27.00 million-$29.00 million to $27.00 million-$29.00 million vs $27.79 million estimate.

Guidance

PPSI

Pioneer Power Solutions Affirms FY2025 Sales Guidance of $27.00M-$29.00M vs $27.79M Est

— Company Estimates Revenue Growth of 40%+ in Q1'25 —
— Company Reiterates Plans to Issue Final Q1'25 Results on May 20, 2025 —
Evolv Technologies Holdings, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>), a leading security technology company pioneering AI-based solutions designed to help create safer experiences, today provided an update on its preliminary financial results for the first quarter of 2025 as well as its upcoming plans to file its related Quarterly Report on Form 10-Q with the Securities and Exchange Commission.
Company Provides Preliminary Update for First Quarter of 2025
The Company today provided an update on preliminary results for the first quarter of 2025. Based on preliminary estimates which are subject to change, the Company expects total revenue to be between approximately $31.0 million and $32.0 million, compared to total revenue of $22.2 million in the first quarter of 2024. The Company expects less than $0.1 million of revenue to be related to the restatement previously completed by the Company. As previously disclosed, as of March 31, 2025, the Company had total cash, cash equivalents, and marketable securities of $35 million, with no outstanding debt. The Company will release final financial results for the first quarter of 2025 on Tuesday, May 20, 2025, after the market closes. Members of the Company's management team plan to host a live webcast at 4:30 p.m. Eastern Time on that day to discuss the financial results as well as management's outlook for the business. The conference call will be webcast live at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fir.evolvtechnology.com&amp;esheet=54255829&amp;newsitemid=20250515290964&amp;lan=en-US&amp;anchor=http%3A%2F%2Fir.evolvtechnology.com&amp;index=1&amp;md5=e090a672c321cba1771ef1925825cbe4">http://ir.evolvtechnology.com</a>.

EVLV

Evolv Technologies Estimates 40%+ Revenue Growth Between $31M - $32M In Q1 2025, Maintains $35M In Cash With No Debt, And Will Release Final Results On May 20, 2025

General

Foot Locker Faces A Potential $59.5M Termination Fee If It Ends The Merger Under Certain Conditions, Such As Changing Its Board Recommendation Or Signing A Superior Deal; Dick's Sporting Goods Risks Owing Foot Locker $95.5M If The Merger Is Terminated Due To Failure To Secure Required Antitrust Approvals

Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) reported quarterly losses of $(0.51) per share.

MOLN

CORRECTION: Molecular Partners Q1 EPS $(0.51)

XChange TEC. Inc. Receives Nasdaq Delisting Determination Letter

Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) reported quarterly losses of $(0.28) per share. This is a 173.68 percent decrease over earnings of $0.38 per share from the same period last year.

ENTO

Entero Therapeutics Q1 GAAP EPS $(0.28) Down From $0.38 YoY

7 analysts have shared their evaluations of IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for IBM, presenting an average target of $261.29, a high estimate of $300.00, and a low estimate of $170.00. Observing a 0.55% increase, the current average has risen from the previous average price target of $259.86. 
<img src="https://www.benzinga.com/files/images/story/2025/1747346488_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of IBM by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$285.00</td>
<td>$276.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>David Vogt</td>
<td>UBS</td>
<td>Raises</td>
<td>Sell</td>
<td>$170.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Erik Woodring</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$233.00</td>
<td>$237.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$276.00</td>
<td>$276.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$265.00</td>
<td>$270.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to IBM. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of IBM compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for IBM's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of IBM's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/IBM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on IBM analyst ratings.</a>
<h2>All You Need to Know About IBM</h2>
IBM looks to be a part of every aspect of an enterprise's IT needs. The company primarily sells software, IT services, consulting, and hardware. IBM operates in 175 countries and employs approximately 300,000 people. The company has a robust roster of business partners to service its clients, which include 95% of all Fortune 500 companies. Primary products include its mainframes, Red Hat software, transaction processing software, and IT consulting.
<h3>A Deep Dive into IBM's Financials</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Positive Revenue Trend: Examining IBM's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.55% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: IBM's net margin excels beyond industry benchmarks, reaching 7.26%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): IBM's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.89% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.75%, the company showcases effective utilization of assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.49, caution is advised due to increased financial risk.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 7 Analyst Ratings Have To Say About IBM

Press Releases

Ostin Technology Group Announces Resounding Success of Pintura Indiegogo Crowdfunding Campaign and Encouraging Sales in Pintura Products on Chinese E-Commerce Platforms

Ostin Technology Group Received Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Ostin Technology Group Announces Results of Extraordinary General Meeting

Ostin Technology Group Announces Effective Date of Reverse Share Split

Ostin Technology Group Announces Update to Effective Date of Reverse Share Split

Ostin Technology Group Announces Participation at CES 2025, Inspiring Greatness with Latest Pintura Products at the Premier Global Technology Trade Show

Comments

Ostin Technology Group

空売り

Ostin Technology Group (NASDAQ:OST) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル